Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpCAM-targeted RNA nanoparticle (SN-38 payload)
- Development stage
- Preclinical
- Lead developer
- RNA NanoBiotics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
RNA NanoBiotics is developing an EpCAM-targeted RNA nanoparticle therapeutic for the treatment of metastatic colorectal cancer. The platform utilizes self-assembling RNA nanoparticles, specifically engineered using 3WJ and 4WJ RNA motifs licensed from Dr. Peixuan Guo, to selectively deliver SN-38 (the active metabolite of irinotecan) to tumor cells expressing the Epithelial Cell Adhesion Molecule (EpCAM). By utilizing a 505(b)(2) regulatory pathway, the candidate leverages the established efficacy of the SN-38 payload while aiming to improve the therapeutic index and reduce systemic toxicities associated with conventional chemotherapy. The modular RNA nanotechnology platform allows for precise control over payload delivery and targeting, potentially offering a more effective treatment option for patients with EpCAM-positive metastatic colorectal cancer.
- Other names
- EpCAM-targeted RNA nanoparticleRNA NanoBiotics EpCAM-SN-38
02
Targets
TOP1 (DNA Topoisomerase I)EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on EpCAM-targeted RNA nanoparticle (SN-38 payload).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpCAM-targeted RNA nanoparticle (SN-38 payload).